- Home
- DSGR vs ELVN Comparison
DSGR vs ELVN Comparison
Compare DSGR & ELVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DSGR
- ELVN
- Stock Information
- Founded
- DSGR 1952
- ELVN 2016
- Country
- DSGR United States
- ELVN United States
- Employees
- DSGR 4400
- ELVN N/A
- Industry
- DSGR Industrial Machinery/Components
- ELVN Biotechnology: Pharmaceutical Preparations
- Sector
- DSGR Industrials
- ELVN Health Care
- Exchange
- DSGR Nasdaq
- ELVN Nasdaq
- Market Cap
- DSGR 1.4B
- ELVN 1.2B
- IPO Year
- DSGR N/A
- ELVN 2020
- Fundamental
- Price
- DSGR $29.12
- ELVN $20.07
- Analyst Decision
- DSGR Buy
- ELVN Strong Buy
- Analyst Count
- DSGR 2
- ELVN 5
- Target Price
- DSGR $40.50
- ELVN $41.20
- AVG Volume (30 Days)
- DSGR 48.2K
- ELVN 435.9K
- Earning Date
- DSGR 07-31-2025
- ELVN 08-12-2025
- Dividend Yield
- DSGR N/A
- ELVN N/A
- EPS Growth
- DSGR N/A
- ELVN N/A
- EPS
- DSGR 0.02
- ELVN N/A
- Revenue
- DSGR $1,866,047,000.00
- ELVN N/A
- Revenue This Year
- DSGR $10.80
- ELVN N/A
- Revenue Next Year
- DSGR $4.10
- ELVN N/A
- P/E Ratio
- DSGR $1,173.65
- ELVN N/A
- Revenue Growth
- DSGR 13.91
- ELVN N/A
- 52 Week Low
- DSGR $21.87
- ELVN $13.30
- 52 Week High
- DSGR $41.47
- ELVN $30.03
- Technical
- Relative Strength Index (RSI)
- DSGR 55.13
- ELVN 43.84
- Support Level
- DSGR $28.14
- ELVN $21.25
- Resistance Level
- DSGR $30.05
- ELVN $22.83
- Average True Range (ATR)
- DSGR 0.80
- ELVN 1.45
- MACD
- DSGR 0.04
- ELVN -0.26
- Stochastic Oscillator
- DSGR 60.48
- ELVN 6.91
About DSGR Distribution Solutions Group Inc.
Distribution Solutions Group Inc is an industrial distributor of maintenance and repair supplies. It has three operating segments namely Lawson, TestEquity, and Gexpro Services, of which key revenue is derived from the TestEquity segment. The TestEquity segment is a distributor of test and measurement equipment and solutions, electronic production supplies, and tool kits from its manufacturer partners supporting the technology, aerospace, defense, automotive, electronics, education and medical industries.
About ELVN Enliven Therapeutics Inc.
Enliven Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. Its product candidates include ELVN-001 is designed to specifically target the BCR-ABL fusion gene product, the oncogenic driver for patients with chronic myeloid leukemia (CML), ELVN-002 is designed to inhibit wild-type HER2 and key mutations of HER2.